initi buy pt
upsid patent decision/competitor data uncertainti
dissip ultomiri beat
initi buy rate pt factor
model us pnh patent aggress impact biosimilar competit
price eros believ stock reflect even wors declin
uncertainti dissip
recommend own alexion buy
karnauska ipr outcom expect august believ investor
anticip win alexion lose soliri pnh patent
believ potenti outcom alreadi factor stock amgen
win see upsid uncertainti remov lose
could even upsid potenti pt
view current valu stock reflect win ipr
price declin keep market share approv indic
credit pipelin see assumpt unrealist
also believ compani could beat consensu estim
see qualiti compani execut repeatedli beat
expect mg growth ultomiri convers
data pnh zilucoplan mg expect
respect evalu head head vs soliri
think could look better soliri underdos patient
believ soliri patient smaller investor
believ rout administr may viabl
ultomiri dose everi two month also believ current level assum
competit model
pipelin deep dive see pg street give zero
credit earli riski estim pipelin could give
upsid success wilson greatest chanc success could
provid upsid
valuat risk pt deriv dcf discount
rate appropri larg cap biotech assum alexion lose ipr
ultomiris/competitiion/biosimilar share assum pnh
price cut soliris/ultomiri pipelin model conserv
risk price pressur greater competit clinic trial failur
tr target
initi buy plu competit landscap analysi pipelin
page
page
bull/bear srth casebul casebear casefair valuepric target valu valu win ipramgn lose ipramgn win ipr biosimilar entri pnh share biosimilar approv indicationsbiosimilar entri pnh share biosimilar approv indicationsbiosimilar entri pnh share biosimilar approv indicationspnh share competitionpnh share competitionpnh share competitionahu share competitionahu share competitionahu share competitiongmg share competitiongmg share competitiongmg share competitionnmosd share competitionnmosd share competitionnmosd share price pressur soliris/ultomiri price pressur soliris/ultomiri price pressur soliris/ultomiri credit pipelineno credit pipelineno credit pipelinedcf base model discount ratedcf base model discount ratedcf base model discount rate inc
pm summari initi buy rate pt
reason think investor buy alexion proprietari research reach thesi
look fundament view investor price us biosimilar launch aggress uptak
 eros mg pnh competit cap uptak mg zero pipelin success
evalu ran worst case sensit pipelin deep dive analysi deep-div
suggest factor could potenti provid upsid current valu
risk/reward buy karnauska ipr good ipr key near-term
overhang decis expect august view ipr loss bake stock could
recov post outcom even win see signific upsid lose ipr bull case
give fv
ultomiri convers may limit biosimilar impact ultomiri convers could off-set potenti impact
biosimilar even scenario ipr loss convers rate report date beaten expect
compani appear track convert pnh patient within year launch kol
doctor check indic push patient back least us soliri convers unlik
model price impact drug conserv
concern around competit done clariti come see data apelli
nr pnh ra rarx hold mg apelli studi head head soliri
believ soliri patient extravascular hemolysi smaller investor believ
second believ rout administr may commerci viabl mani patient
ultomiri dose everi two month also believ current level assum competit model
mg think wors case ra use earlier line clip soliri growth soliri patient like
switch zilucoplan diseas sever
think guidanc consensu mg beaten expect coupl nmo
launch could provid near-term upsid model suggest potenti compani guid
consensu
pipelin deep dive suggest zero credit given data analysi pipelin doc check
due dilig read paper speak doctor speak compani management indic pipelin
still earli carri risk see potenti upsid even singl asset success probabl
wilson diseas would add dcf
page
acknowledg stock hasnt work despit growth believ provid clariti need
alexion share pressur despit continu top-line bottom line
growth margin expans past year
stock hasnt work despit growth execut across board chang
investor concern put pressur stock manag chang late
depend singl drug top-line growth soliri soliri patent concern ipr
overhang potenti biosimilar threat addit competit pnh/ahus/mg -notabl
apelli head head data soliri expect late
evalu perform worst case analysi soliris/ultomiri also pipelin
share price pressur valu pipelin see upsid despit assumpt
beyond one year think assumpt may prove conserv see upsid
stock compani work multipl strategi overcom depend soliri think
alexion sever variabl could off-set impact soliri patent concern
competit ultomiri uptak growth mg nmo near-term pipelin
rate buy pt believ conserv vs consensu
anticip stock go fundament expect cap upsid ahead ipr resolut
august pt conserv reflect ipr loss biosimilar share competit
outsid biosimilar price pressur across multipl indic
page
patent concern biosimilar competit threat caus investor concern despit top
despit compani yoy top-line yoy bottom line growth report last year
beat rais histori encourag launch ultomiri past year stock
vs loss nbi gain
view patent concern around soliri potenti threat biosimilar addit competit
pnh/ahus/mg contribut investor concern
strh research factset
page
stock perform year vs nbi index alexion pharmaceut inc
alexion under-perform despit solid execut base busi
sinc first approv soliri pnh soliri signific contributor alxn
top-line contribut total revenu
pnh market still grow
compani good data mg nmo uptak beat expect
ultomiri approv cannib soliri faster expect us eu/japan
patient convert next gener drug ultomiri exposur soliri biosimilar
reduc far patient convert us
compani expand margin
also invest pipelin diversifi compani
lastli recent announc intend acquir achillion achn nr could pill
complement mediat diseas mani kol excit
page
follow ultomiri approv launch outperform ipr
institut led dip late-august
recent amgen ipr invalid alxn patent pnh institut accept hurt
stock key catalyst compani win ipr would allow
launch biosimilar pnh
get extrapol data ahu could launch biosimilar indic
eu patent protect soliri pnh
amgen ipr institut
august caus
dip stock
strh research factset
page
stock perform vs nbi index alexion pharmaceut inc
wouldnt surpris near term pressur go ipr
file ipr soliri patent case current review ptab decis
expect august
run biosimilar trial ex-u get approv us studi get
extrapol ahu could hurt soliri sale us begin eu biosimilar launch
look fundament think investor price us biosimilar launch share
biosimilar competit price pressur soliri ultomiri across
approv indic think aggress
win ipr anticip biosimilar entri lose ipr model biosimilar
entri research indic rare lost ipr petit
risk/reward good go ipr believ stock current reflect win
note fv scenario ipr loss
page
ask alexion biosimilar competit ipr app run sensit
app allow investor input assumpt biosimilar share competit share price
pressur well view win lose ipr
page
suntrust biotech soliri competition/biosimilar appthi app ase lose patent exclus ipr biosimilar come useurobyn karnauska phd devarakonda phd assum get extrapol approv pnhnicol germino mph announc biosimilar mg yet assum orphan exclusivityminh vong phd announc biosimilar yet nmo yet assum orphan exclus figur million except per share datapeak market share input year ultomiri pnhahusgmgnmoultomiri peak market share year post impact stabl share year stabl share loss ipr outcom select option dropdown win alexion pharmaceut inc
ultomiri convers growth mg/nmo beat expect see guidanc could
consensu
valu million
sourc strh research first order analyt consensu compani report
page
strhconsdeltacommentsalxn franchisesoliri model high digit growth pnh/ahu franchis base compani guidanc gmg gmg build assum continu addit net new patient addit per week also assum continu launch eu japansoliri nmo model modest launch compar gmg in-lin compani guidancetot metabol ww revenu model anticip guidanc beat consensu current valu metabol franchis revenu base patient base model inc
pipelin deep-div indic alxn new pipelin earli carri risk potenti
ultomiri develop new indic get credit
past year invest acquisit syntimmun wilson therapeut achillion
achn nr option acquir caelum cael nr stealth biotherapeut mito nr
establish partnership complement pharma privat zealand pharma zeal-dk nr
affibodi privat expand pipelin
see pipelin earli risk believ street assign valu
pipelin indic model assign valu arriv upsid
strh research compani report
page
worst case scenario analysi indic fv keep third market
indic price impact soliri ultomiri sky scenario
page
bear casestock price base casebullblu scenario scenario ipr win win win loss loss lossalxn share post overhang biosimilar share share impact share post overhang biosimilar share share impact share post overhang biosimilar share competitor share impact share post overhang biosimilar share competit share impact diseas al amyloidosi waihano creditno creditno creditno creditno credit casestock price base casebul caseblu scenario scenario fair valu /shalxn bull/bear scenario inc
risks/pushback like thesi
stock typic well ipr outcom challeng
stock tend poorli elect year given concern around drug price
expect life cycl manag strategi indic note convers
unlik provid increment growth top-line vs soliri given discount pnh discount
indic growth come mg nmo
competit concern apelli pnh mg could creat overhang longer
term look competit landscap concern investor take rout
administr may limit apelli impact mg market big enough alexion ra
take bigger view mani competitor compani complement franchis although
earlier stage develop investor believ alexion cap
uncertainti creat competit landscap
stock reflect biosimilar competit price pushback analysi consensu
beyond could argu long term number need come investor
may want case
recent acquisitions/collabor establish last year enrich pipelin
potenti investor kol skeptic success view lot risk also
see earli first pivot trial pipelin dont read
page
pt deriv dcf
use discount rate think appropri larg cap biotech face
competit threat use termin valu account product capit alloc
summari key assumpt believ conserv reflect investor
strh research compani report
page
figur million ebit stock base net work capit free valu growth tv total share termin total impli assumpt modelpnhahusgmgnmosdultomiri peak market share year post stabl share year brand year post biosimilar impact inc
page
near-term ipr uncertainti creat
alexion patent us protect soliri pnh late
run biosimilar trial europ us site yet pnh
file ipr invalid alexion pnh patent institut accept august
ipr review three soliri patent
proceed progress discoveri oral hear uspto process expect
proceed progress discoveri oral hear uspto process expect
expect outcom august us
stock typic well ipr outcom challeng
patent declar invalid like appeal appeal take anoth month
page
current stat ipr
base timelin biosimilar trial lose see earliest possibl launch biosimilar
win model entri
accord patent expert current institut rate ipr challeng biolog patent
exclud ipr settl otherwis termin
ipr institut gone final written decis forward result
one claim held unpatent
current affirm rate ptab appeal feder circuit
strh research www morganlewi com patent
page
ipr review often key overhang stock though stock reaction mix
case alexion stock massiv perform nbi
think ipr loss factor
therefor stock could recov decis ipr releas august even
lose remov uncertainti
strh research compani report factset
page
stock perform vs nbi index alexion pharmaceut inc
current level think/believ stock reflect potenti ipr loss peak share
indic price reduct soliri ultomiri
strh vs consensu reflect stock price
strh vs consensu reflect pt
believ stock valuat partli reflect ipr overhang also think consensu
number long term may high need come investor may see risk
think clariti biosimilar competit stock recov next moth
strh research factset
page
base case assum ipr win share biosimilar indic
base case assum convers ultomiri ahead biosimilar soliri launch pnh ahu
assum loss share follow biosimilar/competitor entri pnh/ahu
earli data around convers rate encourag view convers defens
move protect exist share rather increas share
addit view convers unlik lead increment growth top-line vs soliri given
discount pnh discount indic
also anticip signific price pressur soliri ultomiri biosimilar entri
page
billionssoliris/ultomiri conversionultomirissoliri inc
view ultomiri convers potenti defend alxn top-line competit
strh research compani report
page
somewhat similar happen teva hold gilbert
teva ms drug copaxon one blockbust drug ww revenu peak first
gener copaxon formul daili dose
ahead patent expir formul may teva launch formul
product week dose regim us januari product also approv
europ decemb
patient convert formul formul copaxon continu
copaxon protect us orang book patent expir european patent
februari us district court rule invalid patent us upheld follow
appeal octob
compani report
page
issu street doesnt believ ultomiri protect despit beat ultomiri
convers movement havent signific therefor think ipr key catalyst
compani manag anticip convers ultomiri back soliri
biosimilar conserv model loss ultomiri share
strh research factset
page
stock perform vs nbi index movementconsensusactualep sale inc
use app see happen win lose
model competit app tab assum win model type win want see dcf
win type lose want see dcf impact soliri protect us biosimilar
still assum competit price pressur conserv
strh research compani report
page
strh biotech soliri competition/biosimilar appthi app ase lose patent exclus ipr biosimilar come useurobyn karnauska phd devarakonda phd assum get extrapol approv pnhnicol germino mph announc biosimilar mg yet assum orphan exclusivityminh vong phd announc biosimilar yet nmo yet assum orphan exclus figur million except per share datapeak market share input year ultomiri pnhahusgmgnmoultomiri peak market share year post impact stabl share year stabl share loss ipr outcom select option dropdown win type lose want see dcf impact soliri revenu competit pnh soliri revenu indic ultomiri revenu convers pnh ultomiri revenu indic \soliri ultomiri soliri ultomiri total revenu inc
view competit landscap exclud biosimilar also concern investor
strh view concern overblown reason
pnh mani compani focus enter market despit trial
compani develop pnh drug attent apelli inhibitor
kol believ like convert patient drug look superior soliri
sever issu may clip penetr view first soliri develop wasnt given dose
high enough individu therefor compar soliri isnt fair comparison vs
ultomiri one dose addit given sub-q push abdomen time week
would take administ amount bodi much higher
inhibitor need ultomiri sub-q given two autoinjector would minut slow
push week conveni
alexion may oral pill pnh alexion acquir factor accord kol could game
changer patient oral may also work ultomiri poor non-respond
mg good phase data think like come market believ
like use ahead ultomiri patient may also prefer less frequent iv ra product daili
inject ultomiri everi month infus view patient current ultomiri soliri
stay worst case view ra clip growth addit market mg much larger
origin estim alexion recent said patient elig soliri
previous therefor could room player final alexion also develop less frequent
compani like nr akari artx nr trial ahu pnh speak
manag think difficult compet soliri focus indic
soliri isnt approv trial serv poc
mg fcrn therapi set enter howev use earlier cours diseas
complement therapi like use fcrn failur view
page
nonetheless competit landscap daunt paper
strh research compani report
page
pnh competit landscap evolv rapidli key defens convers ultomiri
strh research compani report
page
companydrug namemoadevelop stagetrialpati length trialprimari endpointsecondari endpointdrug administr volum time devic triumphplacebo soliri weeksco-primari stabil hemoglobin level transfus breakthrough hemolysi rate proport patient achiev ivh normalizationiv infus long act soliri weeksco-primari stabil hemoglobin level transfus requirementiv infus take hour macrocycl peptid inhibit activ ongoingphas pegasu soliri experienc vs soliri monthsprimari endpoint stabil tranfus avoid reticulocyt ldh facitsc infus mg everi macrocycl peptid inhibit activ initiatedphas nave patient soc exclud complement inhibitor vs monthsco-primari endpoint hgb stabil reduct ldh levelssc infus mg deriv tick saliva target leukotrien on-going capston phase cobaltsoc vs coversin monthsprimari endpoint stabil number unit transfus patient achiev transfus avoid qoi chang ldh area curvesc dailyra pharmazilucoplansynthet macrocycl peptid bind inadequ respons soliri sc target differ epitop vs ongoingopen label singl arm studi cohort dose confirm cohort dose expans pt achiev adequ control ivh proport patient achiev transfus breakthrough hemolysi rate proport patient achiev ivh normalizationsingl iv dose sc human ph depend ongoingpart hv part nave part soliri treat patientsn monthsdl safeti particip termin complement activ patient termin complement activ serum ldh level total sc qw inject volum sc inject volum sc inject volum hucal ab target small molecul target factor ongoingsingl arm trial nave pnh patient two dose drugn year patient reduc hemolysi measur ldh levelschang total free factor upstream monotherapi plan convert next-gen drug soliri combon monotherapi month increas hgb reduct transfus ldh level facit score improvementtwic daili oral administr dose optim factor trial healthi volunt report initi pnh monotherapi switch extens studi daili oral gen compstatin small peptid trial trial pnh expect initiatedn inject everi day inc
head head data expect everi share lost pnh top
model note impact dcf
investig macrocycl peptid inhibitor soliri experienc soliri nave
patient upstream therefor investor believ help anemia seen
pnh patient
data pharoah studi indic stabil hemoglobin level soliri experienc
patient patient success withdrawn soliri
data paddock studi indic potenti reach normal ldh level monotherapi
treatment nave pnh patient
data on-going head-to-head pivot studi soliri experienc pnh patient expect
nave studi data expect
believ pnh patient soliri still suffer anemia feel bad caus
deposit extravascular hemolysi alexion believ less anemia
underli aplast anemia like would treat
believ averag hemoglobin level low soliri alexion argu hb
hb
pt base case assum share competitor pnh biosimilar
pnh howev demonstr superior soliri rout administr deter
uptak think share could lost everi loss share note impact
dcf
page
inhibit stabil hemoglobin level experienc nave pnh patient caveat small trial
data pharoah studi indic treatment normal ldh reticulocyt bilirubin stabil
hemoglobin level soliri experienc patient patient success withdrawn soliri
data paddock studi indic show potenti reach normal ldh level hemoglobin level
near normal rang monotherapi treatment nave pnh patient
page
alexion argu market much smaller theoret risk infect
alexion argu administr challeng lot bodi
need lot drug inhibit
also note recent acquisit achillion give oral inhibitor factor treat
patient apelli go greater eas administr
havent seen small studi target could increas risk infect
shut entir classic complement pathway
kol check pnh doc spoke excit target factor oral option
page
gmg landscap get crowd develop ultomiri anti-fcrn target broader
strh research compani report
page
companyproductdescript productcatalysttimingdrug administrationdatastrch antibodi contain two engin receptor site specifc bind fcrn high affin region prevent igg bind minim impact albumin engin receptor site conjunct two natur fcrn ligand site enabl favor bind kinet fcrn receptor compar trial data weekli sc interim result confirm administr healthi volunt reduc serum igg levelsucbrozanolixizumabhuman high-affin anti-human fcrn mab antibodi inact isotyp reduc likelihood unwant chain exchang trial weekli sc take trial mg pt pbo data report mg-adl respond rate vs placbeo mean reduct serum igg igg autoantibodi headach vs challeng sc formul moder sever headach fulli human anti-neonat fc receptor fcrn aglycosyl immunoglobulin monoclon antibodi engin reduc circul pathogen igg antibodi excess achiev current treatment complet block endogen igg recycl via trial gmg patient monthli twice monthli ivin studi decreas circul igg level mean reduct formul developedargenxefgartigimodefgartigimod target natur fc/fcrn bind site lead fast deplet autoimmun disease-caus igg autoantibodi efgatigimod jiman fc fragment bind fcrn block fc interact recycl elimin igg ig antibodi pivot trial therapi requir administr test efgartigimod treat patient clinic meaning stat-sig improvemnet least consecut studi week vs patient placebo pt achiev clinic meaning respons mg-adl also develop sc formul high product concentr low viscos optim stabil sdc enter human de-immun monoclon antibodi astabil hing mutat design block interact fcrn fc portion igg molecul acid neutral ph order disrupt associ associ pathway relat igg homeostasi innat adapt immun trial weekli iv formul mlg administ hour trial anticip dose studiesno data gmg poc competitorssc formul develop expect target earlier line mg bival anti-fcrn antibody-mimet affibodi sad/mad clinic trial iv investigatedno data yet first studi healthi volunt on-going small size vs mab vs support high-dos low-volum subq dose high bidn affin lead rapid onset activ long half-lif caus long durat action inc
view zilucoplan data encourag low volum subq provid advantag data
small studi look almost better vs soliri
howev real comparison ultomiri potent
page
gmg best launch soliri us help establish neurolog footprint gmg
nmosd launch expect grow patient soliri
mg current alexion biggest growth driver
current patient soliri nmo mg mostli mg compani note
market refractori patient mg bigger thought
believ compani enough time continu penetr market like case
mg new entrant slow growth switch patient
page
life cycl manag gmg underway compani initi trial ultomiri inclus
launch patient pivot trial ultomiri gmg data expect
launch like
inclus criteria broader prior ist failur need vs soliri trial gmg least prior ist
one ist ivig
current model switch soliri patient ultomiri could target larger popul
vs soliri expect tri target earlier patient price would go
give credit expand opportun model compani provid
clariti target popul yet competit fierc gmg ra pharma zilucoplan
well anti-fcrn molecul multipl compani target gmg
non-steroid treat non-refractori patient see peak opportun penetr
note everi peak patient add dcf
page
catalysts/timelin ultomiri view data launch subq formul
like import competit perspect
strh research compani report
page
sensit mg competition- model conserv
ra pharma develop zilucoplan macrocycl peptid target gmg phase trial
on-going data expect daili inject
earli data phase trial demonstr efficaci broad gmg patient popul restrict
refractori case soliri treatment led stat-sig reduct qmg mg-adl
on-going pivot trial ra expect target patient uncontrol diseas
wherea soliri target refractori patient
studi initi octob pivot data expect
pt base case assum refractori patient treat peak declin
share soliris/ultomiri also assum price discount
competition/biosimilar view overli conserv appropri assess stock
trade given investor sentiment ahead data biosimilar
like scenario assum competit clip growth take share
scenario see fv assum reach peak patient
given compani say elig refractori patient could upsid
page
nmosd complement mediat diseas approv drug follow soliri treatment
patient relaps free year
nmosd complement mediat diseas activ complement damag astrocyt caus
inflamm demyelin
diseas mediat pathogen auto-antibodi target protein
key concern patient relaps unpredict lead cumul function
control pivot trial target igg seroposit patient soliri treatment led relaps
prevent patient week patient relaps free year
reduct risk relaps week
page
soliri first fda approv drug nmosd launch earli stage manag pleas
model peak sale everi addit peak sale add dcf
assum target patient popul ww us model ww peak
opportun assum peak penetr us patient compani
report patient number call management note pleas launch
model revenu in-lin consensu pleas ask monthli build
aggress vs consensu nmosd sale earli year also model convers ultomiri
onward cheaper price lower sale outer year
strh research first order analyt
page
first launch strong efficaci even sicker patient known safeti profil posit
competit roch rog-ch nr nr year behind
expect nmosd launch benefit alxn gmg neurolog effort also note
launch like slower mg patient physician educ need nmosd often
misdiagnos ms competit pick follow potenti competitor approv
approv drug indic rituxan use off-label patient
went gener anticip patient soliri rituxan refractori
also anticip new drug nmo reach market roch satralizumab
viela bio inebilizumab howev see use ahead soliri like
assum competit model peak penetr target patient popul could
conserv given effect soliri soliri look effect vs
therapi even though evalu sicker patient
strh research compani report
page
drug/target/trialpati trial design detailsdosingtime-fram veall-com igg seroposit baselin ist least relaps last year relaps last yearseveri vs all-com nobaselin ist least attack last yeareveri vs vs year all-com baselin ist least attack last yearseveri vs vs all-com baselin ist least one attack last attack last yearseveri vs risk relaps relapse-fre week inc
first market numer best result relaps provid initi advantag view
efficaci base relaps free rate indic numer superior advantag
patient relaps free even year week data roch seroposit patient
relaps free somewhat compar trial durat viela week
patient popul trial sicker vs roch viela trial focus
sever popul roch viela focus less sever popul view could
indic drug could work even better healthier patient
igg posit vs all-com alxn trial focus igg posit patient wherea
roch viela enrol all-com demonstr efficaci could potenti restrict
alxn target popul posit patient note nmosd patient
soliri work background ist therapi well monotherapi efficaci monotherapi patient
year viela trial monotherapi roch perform two trial one
background ist one monotherapi soliri look much better efficaci wise popul
viela month could ad advantag vs everi week schedul soliri
dose conveni could potenti deterr alexion first market advantag
effect also footprint neurolog mg experi ultim ultomiri
avail provid attract dose schedul
price soliri price known competitor could price discount lead price
pressur soliri
page
summari model pnh ahu mg nmo- ye conserv
pnh share ultomiri competit biosimilar
ahu share ultomiri competit biosimilar
mg ultomiri competit biosimilar peak treat patient
declin despit popul
nmo ultomiri competit biosimilar despit potenti patient
model patient treat peak declin patient
price model price cut soliri ultomiri competit
page
worst case scenario analysi indic fv keep third market
indic price impact soliri ultomiri sky scenario
page
bear casestock price base casebullblu scenario scenario ipr win win win loss loss lossalxn share post overhang biosimilar share share impact share post overhang biosimilar share share impact share post overhang biosimilar share competitor share impact share post overhang biosimilar share competit share impact diseas al amyloidosi waihano creditno creditno creditno creditno credit casestock price base casebul caseblu scenario scenario fair valu /shalxn bull/bear scenario inc
page
invest signific capit pipelin deliv
alexion actual opportun ultomiri al ppm tma mani way ultomiri could
part compani pipelin
histor key concern investor rest pipelin seem depend upon
soliri ultomiri
last year spent enrich pipelin beyond complement mediat diseas
includ wilson therapeut syntimmun recent achillion acquisit agreement
complement pharma affibodi caelum bioscienc zealand pharma
model assum zero credit new ultomiri indic zero credit pipelin
analysi rest pipelin doc check read paper analyz data speak
manag speak competit indic earli wilson
like offer upsid carri risk credit wilson diseas peak sale note
fv upsid pt
page
believ earli process note low rate drug approv indic
al ppm
assign valu indic note everi peak sale
give credit pipelin equat al hsct-
tma ppm think low probabl didnt assess
pleas ask revenu build
strh research compani report
page
indicationscientific/clin rationalestag developmentpeak strh model/peak opportunitypnhsuccess phase strh model ahussuccess phase strh model refractori gmgsoliri approv gmgphase trial strh model nmosdsoliri approv nmosdphas trial strh model non-refractori gmgsoliri approv gmgphase trial credit alsno poc clinic data scientif rational indic complement activ involv data mix whether target complement activ amelior diseas preclinicallypoc clinic trial initi credit hsct-tmasoliri use off-label reduct tma improv surviv pivot initi credit ppmsno poc clinic data evid elev complement activ seen data support role complement robustexploratori studi evalu complement role ppm expect init credit inc
potenti ultomiri expans opportun al ppm program still earli poc
either indic
arriv opportun al speak compani assum incid
diagnosi rate elig base complement involv assum us eu
compani note narrow band price hh studi said eu
price price
page
despit lack poc data al note evid indic role complement pathway
diseas earli see pharmacolog benefit target pathway
strh research compani report
page
note sever competitor candid clinic develop drug
approv al last year radicava rilutek tiglutik nuedexta
systemat review late stage clinic trial perform last decad al indic mix result
drug test failur rest indic failur rate drug approv
riluzole/rilutek radicava encourag data masitinib
strh research compani report
page
compani name origin product nametargetstherapeut modalityphas developmentab scienc masiviera masitinib masican masipro stem cell factor scf receptor tyrosin kinas c-kit kit moleculeregistrationbiohaven hold co ltd nurtec riluzol moleculeregistrationyooyoung co co ltd mecobalamin moleculephas iiibrainstorm cell inc nurown msc-ntf cell neurotroph factor cell nurown ntf cell applicablestem cellphas iiiorion oral levosimendan potassium channelsmal moleculephas iiiaquest inc riluzol oral solubl film riluzol osf iiiioni inc tofersen dismutas iiigrifol albutein albumin albutein iiamylyx applicablesmal moleculephas iiorphazym a/sarimoclomol shock protein moleculephas iibioelectron technolog iigenervon growth receptor insulin-lik growth receptor iineuralstem inc human neural stem cell hnsc applicablestem cellphas iikyorin co ltd keta ibudilast migrat inhibitori factor mif moleculephas iimedday iiotsuka co ltd nuedexta dextromethorphan/quinidin neurodex zenvia nmda receptor receptorcombinationphas iinutra pharma corp pepteron rpi-mn availablebiologicphas iicytokinet inc reldesemtiv moleculephas ii inc
ultomiri also evalu tma tma common complic follow transplant soliri
use off-label hsct-tma reduct tma improv surviv report
strh research compani report
page
patientsrespons rateindicationtreat follow allogen hsct monthsdramat improv renal functiongener bacchetta bertrand javouhey cheikh sellier-leclerc al pediatr doi epub oct follow autologous/allogen hsct variou weeksdramat improv renal functionjodel fukuda vink mizuno laskin bl goebel dixon bp teusink pluthero fg lu licht davi sm biol blood marrow transplant doi epub dec follow hla-ident weeksimprov tma resolut acut gvhdfernndez lario for cabrera hematol rep dec doi ecollect inc
compani expect initi pivot trial note competit akari
artx nr coversin nr target complement pathway
howev tma face competit complement target therapi alreadi
akari coversin omero behind develop accord speak
manag timelin
ultomiri initi phase see uncontrol phase data
coversin begin phase
end like know competit landscap shape tma
strh research compani report
page
hsct-tmacompani drugmoaindicationtri statustimelin alxnultomirislong-act mab target coversinrecombin small peptid inhibitor deriv tick salivahsct-tma initi trialiniti monoclon antibodyhstc-tmadata uncontrol inc
pipelin enrich beyond soliris/ultomiri multipl acquisit collabor
strh research compani report
page
companytyp transactiond transactiontransact valuecommentswilson drug phase develop treatment wilson diseas rare genet disord hepat neurolog consequ complement co-develop preclin complement inhibitor neurodegen disord option acquir complement pharma term agreementsyntimmun provid lead drug human monoclon antibodi target fcrn drug clinic waiha expect develop gmgcaelum bioscienc develop light chain amyloidosi option acquir caelum base phase data potenti addit payment event exercis acquisit option zealand pharma collabor develop novel peptid complement-medi diseas potenti development-rel mileston sales-rel mileston potenti high singl low doubl digit royalti affibodi co-develop autoimmun diseas potenti addit develop sale base mileston tier low doubl digit royalti payment stealth co-develop emlamipretid follow result pivot trial primari mitochondri myopathi option exercis agreemen provid addit payment devleop function potneti regulatori commerci mileston payment achillion provid achillion first-gen next-gen inhibitor factor could develop combin inhibitor monotherapi alexion pharmaceut inc
deep-div pipelin indic major trial still earli
assign credit program model note potenti upsid
everi peak sale pipelin
pipelin asset model see total addit pipelin valu assign
wilson like offer upsid carri risk credit wilson note fv
add model
compani report strh research
page
develop copper chelat treatment wilson diseas wd treat
chelat therapi level efficaci durabl safeti key concern
wilson diseas copper metabol disord copper accumul liver brain
organ caus liver diseas neurolog psychiatr disord
patient wilson diseas us patient diagnos treat
current standard care includ medic intervent chelators/zinc salt dietari intervent
via low-copp diet liver transplant end stage liver failur
chelat agent commonli use low affin specif copper therapi limit
efficaci safeti multipl daili dose
bind copper high affin specif safe transport blood limit
potenti nephrotox due excret fece kidney like drug
page
medic linetrientinemainten phasefor long accept cu level maintain dietari interventiontyp decopp monthslow-copp dietliv transplantacut end stage liver failureacut end stage liver failurereduc dose chelat zinc wd patient undergo liver transplantsdecopp phase chelat typic use inc
earli data studi encourag drug pivot trial data
earli data encourag open-label single-arm studi newli diagnos patient show
copper reduct treat patient week
mean stabl meld modifi nazer score indic stabl liver function
stat-sig improv mean uwdr disabl score vs neurolog symptom score vs
data extens studi show durabl
compani run patient pivot trial data expect
assign valu program model peak unadjust sale note
upsid dcf everi peak adjust sale valu program note
upsid dcf
view appear differenti current therapi could potenti address
signific unmet medic need wilson diseas
howev speak kol seem mix confid success
page
skeptic investors- address key question
market current patient diagnos treat
discontinu treatment due side-effect profil
anoth copper chelat differenti vs soc affin
specif safeti
trial success show superior
suffici ip protect
look context competit landscap
page
concern market argu yes-
current patient diagnos treat discontinu treatment
due side-effect profil
patient wilson diseas us patient diagnos treat
side effect chelat includ neurolog side effect due increas copper blood
also take long time chelat normal copper level lack complianc
difficult maintain normal copper level
page
current therapi suffici treat wilson accord kol doc check
kol check doc check indic could take month sever year resolut
symptom even decreas copper level patient might need treatment
long period time
even treat complianc rate poor due side-effect drug
caus paradox neurolog worsen patient
page
treatment relat issues/compl patient experi issuesreferencenon-compli treatmentup et al side effect wide use d-penicillamineup et al neurolog worsen upon initi chelat ala et al show neurolog et al liver diseas progress despit treatmentup et al liver transplantationup et al inc
drug expens despit low efficaci side effect
despit lack efficaci advers event profil treatment wilson diseas
expens new class drug approv past sever decad
strh research compani report pricerx
page
concern anoth copper chelat like soc view suffici
differenti vs soc affin specif safeti
primari asset acquir acquisit wilson therapeut
asset differenti vs soc encourag earli data enter trial
kol doctor check note base mechan action caus paradox
neurolog side effect bind cu tightli form complex cant cross blood brain barrier
phase seen
page
kol check indic encourag data includ durabl
earli data open-label single-arm studi newli diagnos patient
encourag copper reduct treat patient week copper reduc
baselin week durabl week mean stabl meld modifi
nazer score indic stabl liver function stat-sig improv mean uwdr disabl
score vs neurolog symptom score vs week
data durabl week irrespect cirrhosi statu
page
data indic copper reduct compar better soc durabl week
without sign neurolog worsen caveat cross trial comparison
bis-cholin ttm stabl
howev ammonium salt ttm shown efficaci use off-label never
commerci unstabl
chart summar data
compani report strh research
page
studi trial trialopen label neurolog preset wd patientsdouble-blind trial neurolog preset wd patient ttm vs trientin double-blind comparison diseas regimen ttm single-arm open label trial drugttmttm regimen ttmbis-cholin ttmttm mg times/day meal mg times/day meal arm mg times/day meal mg times/day meal week ttm regimen mg times/day meal mg times/day meal week daili start dose per day response-guid individu dose depend ncc advers eventstrientin arm meal week ttm regimen mg times/day meal mg times/day meal week mg times/day meal bedtim week durat weeksneurolog tm trientin regimen regimen anemia/leukopeniasa seen transaminas enzym saw increas transaminas revers patient discontinu due alt elev reduct free reduct ttm vs increas free cu trientin regimen reduct regimen patient met primari endpoint mean level uln week reduc week improvementmean uwdr part ii score improv mean uwdr part neurolog examin score improv function stabl base meld naser scoresdos inc
liver enzym elev kol check compani note wouldnt affect use
alt/ast/ggt increas seen liver howev increas bilirubin seen indic
liver injuri one paper suggest could par cours diseas increas
seen higher dose effect seen pt dose revers
liver function stabl patient
sae report case revers alt elev one case neurolog
declin consid drug relat
due occurr side-effect treatment initi titrat
addit kol check note safeti signal noth compar risk copper toxic
liver go untreat
page
concern trial success run patient pivot trial power
demonstr superior vs soc pivot data like take dont know sure
page
demonstr superior key question kol dont know
focu origin design enrol patient power demonstr non-inferior soc
follow interim look effect size trial updat enrol patient power
demonstr superior soc
talk manag learn anoth anticip interim look effect size blind
compani dmc look determin whether size trial need increas order
accord manag trial design base collect inform around effect size time
respons durabl clinic effect seen comparison soc
one kol spoke opin moa suggest drug could superior drug
higher affin also biliari rout effici excret copper
kol concern data control trial support superior claim
management cite mechan action superior wonder patient compliant
soc medicin limit data avail use make cross trial comparison
therefor biggest risk mind hit superior get approv
page
concern suffici ip protect patent protect
year orphan exclus expect extend
bis-cholin tetrathiomolybd patent protect
also note method use patent approv could extend ip
tetrathiomolybd ttm test sever clinic trial past coupl
decad demonstr efficaci wilson diseas howev ammonium ttm shown
unstabl develop appenzeller-herzog et al liver jun doi
though report ttm use year present recommend treatment ttm
limit month
trial indic advantag vs ttm former lead neurolog worsen
also extens patent search indic approv patent applic ttm
deriv date composit matter method use
page
concern competit landscap view gene therapi threat worth note
vivet privat gene therapi still preclin stage
strh research compani report
page
compani nameproduct nametargetsphas developmentmilestonesregulatori designationkadmon hold inc trientin availableregistrationalexion pharmaceut inc decupr bis-cholin tetrathiomolybd dismutas phase data orphan drug track orphan drugneubas tyrosin phosphatas phase i/ii submit cta submit ind orphan drug orphan drug alexion pharmaceut inc
develop anti-fcrn antibodi fcrn affibodi multipl
indic target pathogen autoantibodi
page
target waiha gmg strategi yet unveil
manag note consid menu indic target
term rare autoimmun diseas
due differenti featur longer half-lif smaller volum subcutan administr
compani focus diseas key attribut target patient popul
page
warm autoimmun hemolyt anemia rare diseas affect patient pivot trial
top-line data expect
autoimmun hemolyt anemia aiha character destruct red blood cell due
presenc pathogen igg autoantibodi
waiha common form autoimmun hemolyt anemia pathogen autoantibodi
target rbc temperatur
destruct red blood cell result sever anemia lead weak fatigu
waiha patient may die prematur experienc activ uncontrol hemolysi
approv treatment patient current treat label steroid rituxan ivig
end splenectomi
earli assign credit program model estim peak
opportun peak sale add dcf
page
player target all-com popul see huge potenti opportun
fcrn gmg patient caveat data still earli field competit
develop subq version use gmg pivot trial
product profil subq version like depend high concentr
get volum need inject dose frequenc
expect subq use neurolog nephrolog dermatolog
pivot trial expect initi earli
launch like
expect target less sever patient
soliri ultomiri compani expect cover gmg patient
despit late fcrn game compani expect neurology/gmg footprint
provid advantag
compani report strh research
page
data timelin competitor waiha
strh research compani report
page
bival antibodi extend current sad/mad studi data
could expand fcrn opportun potenti best-in-class subq dose
concern around immunogen albumin reduct
smaller protein molecul base bacteri sequenc staph strep like
higher risk regard potenti immunogen
affibodi lead program similar drug target psoriasi date clinic evid
immunogen report
evalu phase sad/mad studi data expect studi
assess risk immunogen
bind epitop albumin known share overlap bind site albumin
fcrn studi done date reduct albumin
compani report strh research
page
multipl fcrn antagonist clinic trial given data unsur potenti
either first-in-class best-in-class
strh research compani report
page
trial data trial trial gmg patient initiatedpivot trial trial sad/mad clinic trial itp cidpmg hdfnmg itp pemphiguspemphigu waiha mgmg alexion pharmaceut inc
al amyloidosi caus misfold protein made plasma cell affect multipl organ
protract diagnosi period average month signific damag diagnosi
al amyloidosi progress typic fatal diseas caus deposit misfold
light chain piec antibodi made specif plasma cell bone
misfold light-chain clump togeth form amyloid fibril deposit organ
common organ affect heart kidney
symptom frequent mimic diseas chf respiratori distress protenuria often
lead delay diagnosi misdiagnosi
page
base fcrn deep dive think alexion fcrn could inferior inferior
view manufactur issu delay phase compani phase
waiha mg go wait sub-q believ fcrn franchis inferior
follow reason
weekli iv-which commerci viabl given competit kol doctor check
indic may hard make conveni sub-q think bought aby-
sub-q construct bacteria therefor could immunogenc
although seen date
antibodi believ headach associ backbon phase
headach seen
efficaci use week iv health volunt reduct igg vs
potenti seen immunov momenta
pemphigu vulgari patient show efficaci reduct igg week
sub-q longer act appear lower affin could lead lower
efficaci one singl dose show reduct igg
page
current soc chemo prevent futur damag revers earlier
damag asct could potenti cur patient elig
fda-approv therapi al amyloidosi
current soc inhibit plasma cell either tradit chemotherapi agent
proteasom inhibitor immuno-modul often patient fit chemotherapi
current treatment reduc plasma light chain product shut abnorm plasma cell
shut futur amyloid protein product
howev remov previous deposit amyloid protein revers organ damag
asct organ transplant could potenti cur patient elig
median time organ respons current soc month
high morbid mortal al often fatal medial surviv month patient
die within one year diagnosi one year mortal rate approxim patient
cardiac diseas month mean overal surviv sever patient
effect treatment would reduc plasma light chain product elimin exist
light chain amyloid fibril infiltr organ
page
ration design antibodi shown rapid improv function
biomark endpoint clinic studi al amyloidosi patient
page
open-label dose-escal studi patient encourag show surviv
month vs month soc
page
kol check encourag indic interest drug doc
patient data control trial like need doc investor take notic
kol check indic confid strategi drug design ab approach complex feasibl one
one doc indic impress data care approach
data present date encourag indic drug activ seem show effect cardiac
function rel short period time
gl measur shorten heart indic lv function compar shorten expect healthi
subject trial improv shorten posit
one kol note see improv soft tissu amyloid singl patient seen previou year
competit advantag one els level develop belief sinc
failur ab strategi work one kol note strategi potenti use
earli data encourag need see data control larger trial
 would like see improv clinic symptom os indic improv cardiac function
 gl kol note data read blindli machin use read valu critic gl
indic patient sick improv sicker patient need understand clinic
meaning chang
given multipl organ involv kol would like see secondari endpoint differ organ
 cardiac involv would prefer lv volum assess mri endpoint vs ntprobnp respons
consid surrog biomark surviv al amyloidosi
page
alxn recent acquisit achn nr could support alxn
pnh franchis address eros biosimilar competit aplsc
achillion drug target factor upstream factor
critic control point within altern pathway
target altern pathway would leav classic lectin pathway intact fight infect
oral administr would provid advantag subq iv competitor
mechanist factor inhibitor could potenti synerg soliris/ultomiri could help address
address could potenti address competit pressur
page
interim data small phase combo sub-optimal soliri respond show
meaning improv hemoglobin level transfus depend
interim data patient phase trial evalu combin soliri
transfus depend pnh patient soliri treatment indic signific benefit
reduct mean transfus need mean increas hemoglobin gram vs
baselin normal bilirubin ldh reticulocyt count
full phase data readout expect plan advanc combo pivot trial
compani also develop second-gen oral factor inhibitor expect
potenc monotherapi studi pnh patient expect initi
current pt conserv assum share soliris/ultomiri pnh biosimilar
competitor
page
success elus two ab target amyloid deposit failed/termin cael-
specif kappa lambda fibril could differenti vs mab
strh research compani report
address popul patient us eu assum conserv price
believ could peak opportun detail trial design await follow regulatori talk ist-
page
drug nametyp drugmoacompanytri reactiv mabdrug bind amyloid-rel conformt epitop lc-relat fibril inhibit filrillogenesi induc fc-mediat cellular inflammatori respons increas degrad elimin al amyloidoma prevent system lc-associ amyloid depositscaelum biosciences/alxnposit data trial initi expect earli current talk regul around trial target mabdrug bind amyloid fibril prevent format amyloid deposit certain organ facilit clearanc also reduc level amyloid deposit organ prevent organ molecul drug target serum amyloid componentdeplet serum amyloid compon potenti anti-amyloid activ bind circul sap univers compon amyloid deposit form complex rapidli clear human anti-serum amyloid compon antibodydrug bind sap amyloid deposit activ complement trigger rapid clearanc amyloid macrophase-deriv giant cell glaxosmithklineterminateddrug target plasma cell drug approv indic investig al amyloidosisdarzalexmultipl myelomamab target myelomamab target myelomaproteasom inhibitoristend statu unknownninlaromultipl myelomaproteasom inhibitortakedafailedpomalystmultipl myelomaanti-angiogen immunomodulatoristend statu unknownvenclextaheme-onc small molecul inhibitor anti-apoptot protein clinic holdzydeligcl small molecul inhibitor delta isoform istterminatednovel drug target amyloid deposit inc
page
worst case scenario analysi indic fv keep third market
indic price impact soliri ultomiri sky scenario
page
bear casestock price base casebullblu scenario scenario ipr win win win loss loss lossalxn share post overhang biosimilar share share impact share post overhang biosimilar share share impact share post overhang biosimilar share competitor share impact share post overhang biosimilar share competit share impact diseas al amyloidosi waihano creditno creditno creditno creditno credit casestock price base casebul caseblu scenario scenario fair valu /shalxn bull/bear scenario inc
pt deriv dcf
use discount rate think appropri larg cap biotech face
competit threat use termin valu account product capit alloc
summari key assumpt believ conserv reflect investor
strh research compani report
page
figur million ebit stock base net work capit free valu growth tv total share termin total impli assumpt modelpnhahusgmgnmosdultomiri peak market share year post stabl share year brand year post biosimilar impact inc
pt deriv use dcf
use discount factor believ appropri larg cap biotech lower risk
profil competit risk versu peer
assum alexion lose ipr august
soliris/ultomiri make follow assumpt pnh share ultomiri
competit biosimilar ahu share ultomiri competit
biosimilar mg ultomiri competit biosimilar peak treat
patient declin despit popul nmo ultomiri
competit biosimilar despit potenti patient model treat peak
declin patient price model price cut soliri ultomiri
competit
give zero valu pipelin
page
risks/pushback like thesi
stock typic well ipr outcom challeng
stock tend poorli elect year given concern around drug price
expect life cycl manag strategi indic note convers
unlik provid increment growth top-line vs soliri given discount pnh discount
indic growth come mg nmo
competit concern apelli pnh mg could creat overhang
longer term look competit landscap concern investor take rout
administr may limit apelli impact mg market big enough alexion ra
take bigger view mani competitor compani complement franchis although
earlier stage develop investor believ alexion cap
uncertainti creat competit landscap
stock reflect biosimilar competit price pushback analysi consensu
beyond could argu long term number need come investor
may want case
recent acquisitions/collabor establish last year enrich pipelin
potenti investor kol skeptic success view lot risk also
see earli first pivot trial pipelin dont read
page
strh resesarch compani report
page
incom statement market productsproduct revenu sale pediatr unadjustedultomiri non-refractori al product oper oper itemsinvest interest incom currenc gain expens incom exc spec tax incom non-gaap cash tax excl stock ep ex-opt tax net incom non-gaap ep incl share share share dilut use non-gaap inc
strh resesarch compani report
page
balanc sheet asset cash manufactur expens current current plant equip asset manufactur liabilitiesaccount credit portion long-term debt portion capit leas current current leas oblig less current revenu less current debt oblig less current stockhold liabil inc
statement flow
strh resesarch compani report
page
statement flow oper net incom gaap non-oper item depreci compens dispos properti plant oper asset liabil account expens payabl accru cash provid oper flow invest purchas market matur sale market properti plant restrict cash use provid invest flow financingpay capit leas revolv credit proce debt mortgag issuanc treasuri proce issuanc common exchang rate chang inc
ludwig hantson ph chief execut offic alexion
dr hantson accomplish healthcar execut year experi biopharmaceut
prior join alexion dr hantson presid chief execut offic baxalta also serv
compani board director
dr hantson join baxter may establish bioscienc divis
dr hantson held sever leadership role decade-long tenur novarti includ ceo
pharma north america ceo europ presid pharma canada
prior novarti spent year johnson johnson role increas respons market research
develop
dr hantson receiv ph motor rehabilit physic therapi master degre physic educ
certif high secondari educ univers louvain belgium
brian goff execut vice presid chief commerci global oper offic alexion
role lead global commerci oper team includ respons countri oper
alexion affili north america europ japan asia pacif latin america prior join alexion mr
goff chief oper offic member board director neurov
prior join neurov mr goff serv baxalta execut vice presid presid hematolog divis
previous serv baxter healthcar corpor global hemophilia franchis head
earlier career mr goff held posit increas respons sale market role novarti
pharmaceut pharmaceut divis johnson johnson
mr goff wharton school univers pennsylvania bachelor art skidmor
page
john orloff execut vice presid head research develop alexion
dr orloff year experi biopharmaceut industri deep expertis span variou stage
develop includ develop medicin rare diseas
prior join alexion dr orloff serv execut vice presid head research develop novelion
previous serv baxalta global head chief scientif offic
also held execut role merck serono novarti merck research laboratori
prior join biopharmaceut industri dr orloff yale school medicin seven year
dr orloff receiv bachelor art dartmouth colleg univers vermont colleg
medicin complet medic train univers pittsburgh medic center yale univers school
dr sarin join alexion novemb drive strategi busi develop serv alexion chief
busi strategi offic prior becom chief offic
bring alexion year profession experi global financi institut
prior join alexion dr sarin manag director healthcar corpor invest bank citi global
bank focus client life scienc biopharmaceut sector
serv manag director healthcar invest bank ub work jp morgan
 advisori healthcar group focus transact execut
bank career dr sarin train medic doctor india spent two year practic india
dr sarin complet medic train univers delhi receiv stanford busi school
page
manag compens align well sharehold interest
overal compens plan appear line sharehold interest name execut
offic elig earn incent bonu base individu perform goal well
corpor goal relat product develop advanc clinic studi
compens execut structur around achiev corpor goal
mileston year base subject object perform goal
determin board director
page
alexion pharmaceut inc biopharmaceut compani focus serv patient
devast ultra-rar disord develop commerci life-
transform therapeut product compani product includ ultomiri soliri strensiq
kanuma compani found joseph madri david keiser stephen squinto
leonard bell januari headquart boston
buy-rat share next month think
investor clariti us pnh patent see risk reward buy
karnauska ipr favor current level recommend own alexion
ipr outcom august believ investor expect win alexion
lose soliri pnh patent win see upsid uncertainti remov
lose could even upsid pt
view current valu stock reflect invalid alexion us pnh patent
price pressur soliri keep market share approv indic
credit pipelin believ unrealist given convers ultomiri go ahead
expect model give signific share biosimilar us eu
also believ compani could beat consensu estim see qualiti
compani execut repeatedli beat expect mg growth ultomiri
see data apelli nr pnh ra rarx hold mg apelli
studi head head soliri believ soliri patient extravascular
hemolysi smaller investor believ rout administr
challeng mani patient ultomiri dose everi two month also believ current
level assum competit model
acknowledg stock may achiev upsid tp ahead ipr
uncertainti consensu estim beyond appear erod alexion
busi much may need come
valuat risk
pt deriv use dcf use discount factor believ appropri
larg cap biotech lower risk profil competit risk versu peer assum
termin valu reflect alexion creat valu cash gener assum alexion lose ipr
august soliris/ultomiri make follow assumpt pnh share ultomiri
competit biosimilar ahu share ultomiri competit
biosimilar mg ultomiri competit biosimilar peak
treat patient declin despit popul nmo ultomiri
competit biosimilar despit potenti patient model treat
peak declin patient price model price cut soliri ultomiri
competit give zero valu pipelin
risk rate price target includ price share erod greater faster expect
greater competit clinic trial failur pipelin
compani mention note
page
samsung bioepi xkrx-korean might privat
robyn karnauska herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
page
